Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 20/20 | 0.42 |
| ▸ | GSK3A | P49840 | 18/20 | 0.42 |
| ▸ | PRKCB | P05771 | 2/20 | 0.37 |
| ▸ | CDK4 | P11802 | 2/20 | 0.37 |
| ▸ | CDK2 | P24941 | 2/20 | 0.37 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.37 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.37 |
| ▸ | CAMK2G | Q13555 | 1/20 | 0.37 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.37 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6806997 | 0.88 | GSK3B (0.46) | GSK3BGSK3APRKCBCDK4CDK2 | |
| SCHEMBL6803328 | 0.87 | GSK3B (0.41) | GSK3BGSK3APRKCBCDK4CDK2 | |
| SCHEMBL6801058 | 0.86 | GSK3B (0.43) | GSK3BGSK3APRKCBCDK4CDK2 | |
| SCHEMBL6802576 | 0.79 | GSK3B (0.37) | GSK3BGSK3APRKCBCDK4CDK2 | |
| SCHEMBL6802735 | 0.78 | GSK3A (0.64) | GSK3BGSK3A | |
| SCHEMBL6327468 | 0.76 | CDK4 (0.35) | GSK3BGSK3APRKCBCDK4CDK2 | |
| SCHEMBL6799174 | 0.74 | GSK3B (0.54) | GSK3BGSK3APRKCBCDK4CDK2 | |
| SCHEMBL6327416 | 0.74 | GSK3B (0.33) | GSK3BGSK3APRKCBCDK4CDK2 | |
| SCHEMBL6849576 | 0.73 | GSK3B (0.46) | GSK3BGSK3APRKCBCDK4CDK2 | |
| SCHEMBL3059812 | 0.72 | HTR1A (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1250334-B1 | Medicaments useful for the treatment of proliferative diseases | LILLY CO ELI (US) | 2004-05-19 | — | — | EP | claimed |
| US-6743785-B2 | KINASE INHIBITORS; ANNULATED PYRROLE AND INDOLE RINGS; PYRROLO (3,2,1-HI)INDOLES; 3-(5,5-DIMETHYL-5,6-DIHYDRO-4H-PYRROLO (3,2,1-IJ)QUINOLIN-1-YL)-4-(1,2,3,4-TETRAHYDRO-(1,4) DIAZEPINO(6,7,1-HI)INDOL-7-YL)-PYRROLE-2,5-DIONE | ELI LILLY AND COMPANY | 2004-06-01 | — | — | US | disclosed |
| EP-1250334-B1 | Medicaments useful for the treatment of proliferative diseases | LILLY CO ELI (US) | 2004-05-19 | — | — | EP | disclosed |
| US-20030092676-A1 | Agents and method for the treatment of proliferative diseases | ELI LILLY AND COMPANY | 2003-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092676-A1 | Agents and method for the treatment of proliferative diseases | MKI67, CDKN1A, CDK4 | GSK3B 761/4885GSK3A 699/4885PRKCB 152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.